Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

AB0078 PREDICTORS OF HOSPITALIZATION DUE TO BREAKTHROUGH COVID-19 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES: DATA FROM SAFER STUDY

2024; BMJ; Linguagem: Inglês

10.1136/annrheumdis-2024-eular.3649

1468-2060

Débora Cerqueira Calderaro, K. Lysie Libardi Lira Machado, Edgard Torres dos Reis Neto, S. Lúcia Euzébio Ribeiro, M. Gomes Gouveia, Laiza Hombre Dias, Débora Marques Veghini, R. Casian Tuão, K. Rosemarie Lallemand Tapia, M. Barbosa Beloni Lirio, Marcelo Lima, Filipe Faé, Laíssa Fiorotti Albertino, J. Ribeiro de Oliveira, H. Corona, Isac Ribeiro Moulaz, L. Gonçalves Rodrigues Aguiar, Priscila Dias Cardoso Ribeiro, Vanessa de Oliveira Magalhães, Mariana Freitas de Aguiar, Erika Biegelmeyer, Flávia Maria Matos Melo Campos Peixoto, Cristiane Kayser, Alexandre Wagner Silva de Souza, Charlles Heldan de Moura Castro, Camila Maria Paiva França Telles, Juliana Bühring, R. Lima, R. Holanda Da Silva Sanches, Natália Seixas de Melo, Chiho Yasuda, Natália Sarzi Sartori, V. Hax, Rafaela Cavalheiro do Espírito Santo, Rodrigo Poubel Vieira de Rezende, Kátia Lino, Natália Rodrigues Querido Fortes, Ana Karla Guedes de Melo, T. Santos Melo, V. Cruz, Jozélia Rêgo, Rejane Maria Rodrigues de Abreu Vieira, Adah Sophia Rodrigues Vieira, Adriana María Kakehasi, Anna Carolina Faria Moreira Gomes Tavares, Aline Teixeira de Landa, Paula Priscila Correia Costa, Valderílio Feijó Azevedo, Olindo Assis Martins‐Filho, Vanessa Peruhype-Magalhães, Marcelo Maia Pinheiro, Emília Inoue Sato, Odirlei André Monticielo, Ricardo Machado Xavier, A. Teixeira‐Carvalho, Viviane Angelina de Souza, Gilda Aparecida Ferreira, Valéria Valim, Gecilmara Salviato Pileggi,

Dermatological and COVID-19 studies

Background: Breakthrough COVID-19 infections occurring in fully vaccinated people have been described. There is particular concern about the effectiveness of vaccination in patients with immune-mediated rheumatic diseases (IMRD). Data on the characteristics and prognosis of breakthrough COVID-19 among IMRD patients are scarce. Objectives: To describe demographic and clinical characteristics, COVID-19 presentation, and risk factors associated with hospitalization in this population. Methods: SAFER study is a Brazilian multicentric cohort evaluating safety and effectiveness of SARS-Cov-2 vaccines in patients with autoimmune diseases, ongoing since April, 2021. In this study, 1,128 fully vaccinated adult IMRD patients were analyzed. It describes the fully vaccinated IMRD patients presenting breakthrough COVID-19 (occurring ≥14 days after the second dose in a two-dose series or ≥14 days after a single-dose vaccine), from April, 2021 to February, 2023. Descriptive analysis, and a regression model to evaluate the variables associated with hospitalization due to COVID-19, were performed. The significant p-value was < 0.05. Results: 160 fully vaccinated IMRD patients surviving breakthrough COVID-19 were included. Patients received 2 (19%), 3 (70%) or 4 (11%) vaccine doses. The initial two-dose series was mainly with ChAdOx1 (Oxford/AstraZeneca) (58%) or BBIBP-CorV (Sinopharm-Beijing) (34%). The first booster (n=150), with BNT162b2 (BioNtech/Fosun Pharma/Pfizer) (63%) or ChAdOx1 (Oxford/AstraZeneca) (29%), and the second booster (n=112) with BNT162b2 (BioNtech/Fosun Pharma/Pfizer) (40%) or ChAdOx1 (Oxford/AstraZeneca) (26%). The characteristics of the population are shown in Table 1. Most (96%) patients reported COVID-19 symptoms, mainly headache (57%), cough (54%), rhinorrhea (51%), sore throat (49%), fever (46%), fatigue (32%), hyposmia (20%), dysgeusia (18%), and dyspnea (18%). Binary logistic regression for hospitalization due to breakthrough COVID-19 is in Table 2. Conclusion: Booster vaccine doses decreases, while higher disease activity or chronic use of corticosteroids increases the risk of hospitalization due to breakthrough COVID-19 infection in IMRD vaccinated patients. Fever or dyspnea in COVID-19 infection predict hospitalization in this population. New studies to evaluate the impact of breakthrough COVID-19 and the effects of vaccine booster doses in these patients are warranted. REFERENCES: NIL. Acknowledgements: We thank SAFER Study Group and the Brazilian Society of Rheumatology for supporting this study. This study was financed by the Brazilian Department of Science and Technology (TED 20/2021). Disclosure of Interests: None declared.